Company: MIRA
Filing Date: 2025-03-13
Form Type: 8-K
Source: 0001493152-25-010140
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-13
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA) (“ MIRA” or the “ Company”), a clinical-stage pharmaceutical company neurological and neuropsychiatric disorders formulation
of Ketamir-2 into a topical treatment neuropathic and inflammatory pain pain management pipeline Ketamir-2 oral treatment for neuropathic pain targeted approach
for localized pain relief

The topical formulation of Ketamir-2 slow release targeted pain relief at the site of application
while minimizing systemic exposure currently conducting an ongoing preclinical study efficacy
of this new topical formulation in treating inflammatory pain

As
a clinical-stage company topical treatment for potential future clinical
trials ongoing Phase 1 clinical trial for the oral formulation Phase 2a study in diabetic neuropathy by year-end first human efficacy data by Q1 2026

For
more information, please visit www. mirapharmaceuticals. com

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                      MIRA                                         
  Dated:              By:                       /s/                
                      Name:                     Erez               
                      Title:                    Chief